Nektar Therapeutics’s filing revealed that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $62802.0 on Nov 25 ’25. In the deal valued at $54.28 per share,1,157 shares were sold. As a result of this transaction, Zalevsky Jonathan now holds 18,971 shares worth roughly $1.14 million.
Then, Wilson Mark Andrew sold 630 shares, generating $34,196 in total proceeds. Upon selling the shares at $54.28, the Chief Legal Officer now owns 21,585 shares.
Before that, ROBIN HOWARD W sold 2,207 shares. Nektar Therapeutics shares valued at $119,796 were divested by the President & CEO at a price of $54.28 per share. As a result of the transaction, ROBIN HOWARD W now holds 54,245 shares, worth roughly $3.27 million.
H.C. Wainwright reiterated its Nektar Therapeutics [NKTR] rating to a Buy in a research note published on June 24, 2025; the price target was $120. A number of analysts have revised their coverage, including BTIG Research’s analysts, who remained covering the stock and in late June has reiterated a ‘”a Buy”‘ rating for it. Jefferies also remained covering NKTR and has increased its forecast on April 11, 2025 with a “Buy” recommendation from previously “Hold” rating. Oppenheimer revised its rating on March 14, 2025. It rated NKTR as “an Outperform” which previously was an “a Perform”.
Price Performance Review of NKTR
On Tuesday, Nektar Therapeutics [NASDAQ:NKTR] saw its stock jump 2.92% to $60.35. Over the last five days, the stock has gained 1.99%. Nektar Therapeutics shares have risen nearly 298.35% since the year began. Nevertheless, the stocks have risen 332.62% over the past one year. While a 52-week high of $66.92 was reached on 10/31/25, a 52-week low of $0.43 was recorded on 04/09/25.
Levels Of Support And Resistance For NKTR Stock
The 24-hour chart illustrates a support level at 58.57, which if violated will result in even more drops to 56.80. On the upside, there is a resistance level at 61.56. A further resistance level may holdings at 62.78.
How much short interest is there in Nektar Therapeutics?
A steep rise in short interest was recorded in Nektar Therapeutics stocks on 2025-11-14, growing by 81526.0 shares to a total of 1.81 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 1.73 million shares. There was a rise of 4.5%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 08, 2025 when B. Riley Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $4 price target.
